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ABSTRACT
In this paper we examine the level of user innovation activity
related to different brands of the same type of product - automated clinical
chemistry analyzers. Strong interbrand differences are found in user involve-
ment in such innovation tasks as the development of new chemical test methods
for use on the different analyzers studied. We test the speculation of inter-
viewees that the cause of the differences observed lies in details of the design
of the analyzers studied which makes some easier for users to modify than others,
and find it supported by our data. As product design is a variable under the
control of product manufacturing firms, this finding suggests that manufacturers
can, it at least some product categories, influence the level of user innovation
related to their products via product designs which encourage or discourage such
activity. Related costs and benefits are discussed.
1.0 Introduction
Students of the technological innovation process have long sought
characteristics of firms, industries, technologies, regulatory environments,
etc. which correlate with and might contribute to successful innovative activity.
Over the past few years, one of the variables studied to this end has been the
role of the user in the industrial product innovation process. 'To date, it has
been shown that in some industries, users play a major role in that process -
actually developing 60-80% of the innovative products sampled(1'2) - while in other
industries, the user appears to play a minor role, with most products sampled
being developed by the product manufacturer.(3 '4) In still other industries, the
proportion of product innovations developed by users has been seen to diminish
relative to that of product manufacturers with the passage of time.(5)
All of the above-cited studies provide data on the innovation role
of the user at a fairly high level of aggregation ("industry", (6)technical
area"(9)). Logically, therefore, speculation as to the causes of the patterns
seen has also tended to revolve around industry-level variables. It is important
to keep in mind, however, that variables operating at the level of the individual
firm and even the individual product may also have an important impact on the
role of users in the innovation process. In this paper, we will test the propos-
ition that the innovation role of the user can be seen to differ significantly
between products which are functionally very similar. We will then go on to
suggest that a variable operating at the level of the individual product - product
design - may play a role in creating the differences observed.
2.0 Type of Product to be Examined
The type of product which we have selected for study is the automated
clinical chemistry analyzer. Our decision to explore this product type was not
derived from theoretical insight. Rather, two eminently practical considerations-
I
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were determining:
1) One of the authors (S.F.) is' a physician specializing in clinical
chemistry.
2) A great deal of product innovation has taken place in the category
in the last 20 years.
Readers unfamiliar with automated clinical chemistry analyzers and
their'uses may find some contextual information helpful. Automated clinical
chemistry-analyzers are used in clinical laboratories - a large and growing industry.
(Accordng to Smithson,(8)there were approximately 14,000 clinical laboratories in
the U.S. in 1975. Some 50% of these were affiliated with hospitals, 30% were
affiliated with M.D. offices, and 20% were independent commercial entities. Their
aggregate revenues were on the order of $6.2 billion in 1975 and growing at 10%
annually.) The role of clinical laboratories is to perform tests on samples of
human body fluids and tissues at the order of physicians or other health care
practitioners. Test results are reported back to these practicioners for use in
the diagnosis and management of their patients.
Tests performed by clinical laboratories are traditionally divided
into the four major categories of clinical chemistry, hematology, bacteriology,
and serology. Those in the clinical chemistry category - the one we will examine -
are used to determine the level of a chemical, such as glucose, in a patient's
blood. Typically there are several "methods" available by which a particular
"test" (such as blood glucose) can be performed. The execution of a clinical
chemistry test method involves combining a sample of a patient's serum with one
or more reagents and then allowing the chemical reaction(s) thus initiated to
take place under prescribed conditions of time, temperature, etc. Substances
which would interfere with the test measurement are removed (by precipitation,
dialysis, or other means), the test measurement is made (via techniques such
as colorimetry, flourometry, etc.) and the test result recorded.
III
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Since the 1950's,- automated clinical chemistry analyzer equipment
has been available which, as the name implies, can carry out clinical chemistry
tests automatically. Such equipment has been widely adopted despite prices on
the order of $20-200 thousand dollars per unit (Reportedly 9)44%of the 677mm
clinical chemistry tests performed in hospital labs in the U.S. in 1977 were
performed on automated clinical chemistry analyzers). Automated clinical
chemistry analyzers are said to be cost-effective because they reduce the labor
content per test from the 50% which was the rule of thumb for manual methods to
about 5%, while at the same time reducing the incidence of test errors.
3.0 Speculations Regarding Analyzer-
Based Test Development by Users
Manufacturers of automated clinicai chemistry analyzers usually also
specify procedures and sell materials (pre-mixed reagents, etc.) which can be
used together with their equipment to perform certain frequently-requested
clinical chemistry tests. Analyzer users who wish to perform a commercially-
available test by a method different than that offered by the manufacturer -or
who wish to perform a test not commercially available - must develop an analyzer-
compatible method on their own or find an appropriate method reported in the
research literature.
It seemed to us that manufacturers of automated clinical chemistry
analyzers should find such user method development activity involving their equip-
ment of potential interest because:
- the value of a clinical chemistry analyzer is, obviously, a function
of the tests it can perform
- test methods developed for use on one type of analyzer usually cannot
be transferred to another type without adaptation work - and sometimes
cannot be transferred at all because of differences in equipment
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operating characteristics.
We therefore decided to explore our speculation that different types of function-
ally similar products (here, different types of automated clinical chemistry
analyzer) could show significant differences in the innovation role of the user
by exploring extant user test development activity involving different types
of automated clinical chemistry analyzer.
Our examination of this issue was begun by contacting several prof-
essionals in clinical chemistry labs who had recently published research involving
the use of automated clinical chemistry analyzers. We asked these analyzer users
whether any of the three brands of automated analyzers most commonly available in
**)hospital clinical chemistry labs in 1977 (Technicon, DuPont, and Abbott were
more likely to be used in the development of new clinical chemical test methods
by users than others. All contactees felt that Technicon and Abbott Labs equip-
ment was quite likely to be used for this purpose but DuPont equipment was not
likely to be - and that the reason involved a particular aspect of the design of
the analyzers manufactured by these companies. More specifically, they suggested
that the design of the "reagent system" portion of the DuPont autoanalyzer equip-
ment presents a major barrier to any non-DuPont personnel who might wish to
develop chemical test methods for use on it, and that such a barrier does not
A generally accepted definition for what constitutes "automated" equipment for
the performance of such tests does not exist. IMS (cf.** below) solves the
problem in its surveys by asking respondents to indicate whether "automated
chemistry analyzers, such as AutoAnalyzer or Robot Chemist [were used]." Auto-
Analyzer and Robot Chemist are the brand names of equipment which, when given
a blood serum sample as an input, will perform all the steps required to
execute a chemical test automatically and present a test result to the technician
on a meter or printout as output. The equipment we will study fits these
performance criteria.
** (9)Source of data is IMS. IMS generates its data by surveying and auditing lab
records of 204 of the approximately 5,800 non-federal, short term hospitals in
the U.S. The sample of hospital labs used in stratified by bed size, region,
and hospital ownership. IMS restricts circulation of its data; it is used here
by permission of the company.
exist on the Technicon and Abbott Labs equipment. Telephone interviews with
product managers in the Technicon, DuPont and Abbott Labs automated analyzer
groups yielded a similar assessment and interpretation.
When we studied the design of analyzers built by these three manufac-
turers, the interviewees opinion on this issue seemed to us to pass a "test of
reason" with ease. So that our readers may have an opportunity to make this
judgement for themselves, we provide capsule descriptions of the portions of the
DuPont, Technicon and Abbott Labs automated analyzer systems which are relevant
to the issue.
- DuPont automated clinical chemistry analyzer systems can be seen as
made up of two major components, the analyzer equipment itself and single use,
disposable, factory sealed "test packs" supplied by DuPont. DuPont currently
offers owners of its analyzer equipment-factory-supplied methods for thirty six
tests, each requiring a test pack tailored for that test-method only. The test
packs are complex and carefully designed to be "fool-proof" - e.g., usable-even ;
by minimally trained operators. They consist, in essence, of plastic pouches
divided internally into several sealed compartments which contain reagent quant-
ities needed for a single execution of a particular test. The pouches, in turn,
are sealed to a plastic "header" which contains a serum inlet valve and, for
tests which require it, a built in chromatographic column for one-time use which
removes substances which would interfere with the needed test measurement. All
chemical reactions required for a test occur inside the disposable test pack - the.
pack itself is never opened during its transit through the analyzer equipment.
Even the results of the test are determined without opening the pack, by passing
Technicon offers several models of automated clinical chemistry analyzer, Abbott
Labs offers two models and DuPont one. All models of a given manufacturer are
fitted with the same type of reagent proportioning system, however. As a
consequence, we will be able to examine the interviewees' hypothesis by collecting
data on analyzer brands rather than on specific models of analyzer.
_____1_--_11____.-
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a light beam through its transparent walls.
- Technicon automated clinical chemistry analyzer models are based on
a principle called "continuous flow analysis", and function much like miniature,
continuous-process chemical plants. Technicon's product design philosophy over
the years has been to build a series of functional modules - e.g. pump modules,
dialyzer modules, etc. - which may be used as system building blocks. Systems
capable of performing a particular chemical test are assembled by selecting
certain of the available modules and interconnecting them into appropriate
hydraulic circuits by means of small-diameter plastic tubing. Tests are then
run by supplying reagent, patient serum samples and compressed air (used to create
bubbles of air in the tubing which isolate one patients test material from
another's) to appropriate points in the hydraulic circuits. Pump modules in the
system combine these in the proper proportion and sequence and move them through
the system to accomplish the test.
Technicon offers its customers standardized assemblies of modules
and tubing for the performance of the test methods it makes available commer-
cially. Modules and tubing may also be purchased separately, however, and
experimenters who wish to may quickly and conveniently assemble these into unique
configurations which will allow them to perform test methods not offered commer-
cially.
- Abbott Labs automated clinical chemistry analyzers meter the amount
of reagent(s) needed for a particular test from bulk reservoirs into transparent,
disposable, open-topped plastic cups called "cuvettes". Samples of patient serum
are also metered into these cuvettes and the desired reaction is allowed to proceed
at a specified temperature and for a specified time. When the required time has
elapsed, individual test results are "read" by passing a beam of light through
the transparent walls of individual cuvettes. Users may either fill the reagent
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reservoirs with Abbott-specified materials or with materials of their own
design.
On the basis of the above capsule descriptions of portions of the
DuPont, Technicon and Abbott Labs automated analyzer systems, the reader may now
be in a position to appreciate why users would find it easier to develop and
execute test methods not available commercially by using Technicon or Abbott
Labs equipment-than by using DuPont equipment. Techniicon modules may be purchased
and connected up in a novel configuration. In both Technicon and Abbott equip-
ment, desired novel reagents can be mixed up in bulk, placed in the machine's
reservoirs, and the machine will meter out the proper amount of reagent(s) and
serum needed for each test. Setting up-the same novel method on DuPont equip-
ment, on the other hand, starts with buying empty test packs from DuPont (empty
packs without chromatographic columns are for sale: They have a standard use
in machine calibration). Given that the test can be done by using the size and
number of reagent compartments available in the empty pack, the experimenter
must next inject precisely measured amounts of reagent into selected compartments
of each pack and then reseal the compartments. If 1,000 tests are required for
an experiment, he must perform these operations on 1,000 packs. This would
clearly be a great effort - and the end result would be the accomplishment of
a reagent porportioning task which Technicon and Abbott Labs equipment does
automatically.
4.0 Test of the Speculation
In the preceeding section, we discussed the speculation of interviewees
that Technicon and Abbott Labs automated clinical chemistry analyzers were more
likely to be chosen by users for research involving the development of new
clinical chemistry test methods than were DuPont analyzers. We should now note
that development of novel test methods is not the only kind of clinical chemistry
research engaged in by users: They also conduct research involving test methods
commercially supplied by analyzer manufacturers when such-are appropriate.
(e.g.: "The blood glucose level of 300 type Y patients was determined via the
method sold by DuPont for use on its automated clinical analyzer equipment
and it was found that ... ".) The existence of these two types of research by
users of automated clinical chemistry analyzers - (l)-research involving test
methods made commercially available by equipment manufacturers tiand i(2) research
involving test methods developed by users themselves -suggests a way by which
we can test the speculation of the interviewees. If DuPont automated clinical
chemistry analyzers are less appropriate for research involving user developed
test methods than are the Technicon and Abbott Labs analyzers, then this should
be visible in the research literature: That is, the ratio of research reports
involving commercial vs. user-developed test methods should be significantly
higher when DuPont analyzers are used in the research than when Technicon or
Abbott Labs analyzers are used.
We decided to test the above hypothesis by means of MEDLINE, a comput-
erized index of the medical literature made available by the National Library of
Medicine, Bethesda, MD. The MEDLINE system provides access to articles published
in most biomedical journals (approximately 3,000) from 1964-1975 to the present
via title, author, "subject heading" and "textword". ("Subject headings" are
assigned to articles by indexers working for the National Library of Medicine
as a function of the subject matter dealt with in the article. A thesaurus of
standard subject headings is maintained for use by indexers and those wishing to
retrieve citations by use of these. "Textwords" are simply any word or combin-
ation of words. Users of the system may specify textwords and the system will
flag articles containing them in the article title and/or abstract. Abstracts
of most articles are contained in the MEDLINE data base from 1975 to present.)
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We began our test by determining from the MEDLINE thesaurus(10) that
"autoanalysis" was the subject heading assigned to papers involving the use of
clinical chemistry autoanalyzers. Next, we decided to search the.data base
from the period January 1975 - the date article abstracts were first incorporated -
to January 1978. (The search was performed in April, 1978, and at that time
the most recent articles in the data base were published in January, 1978.) The
system was instructed to identify articles which indexers at the National Library
of Medicine had coded under the subject heading "autoanalysis", which also
contained the names of DuPont, Technicon or Abbott Labs as "textwords" in the
articles" title and/or abstract. Copies of the papers thus identified were
obtained and examined by the authors. Those found to report research involving
use of automated clinical chemistry test equipment manufactured by the named
firms were coded according to the content categories of table 1 and the result-
ing citation counts entered into the data columns of the table.
Insert Table 1 Here
Note that this citation-search procedure does not identify all research public-
ations involving autoanalyzer equipment. Rather, only that - possibly small -
subset which names the equipment manufacturer in title and/or abstract is ident-
ified. Total citations found for each instrument brand is an indicator of the
relative frequency of brand usage for research purposes if we assume that authors
have no significant interbrand bias regarding explicit identification of the
manufacturer of equipment used in title and/or abstract. The test we wish to
make, however, - relative frequency of two categories of research usage for each
of three brands of analyzer - is independent of such an assumption .
As will be seen from table 1, the results of our test support the
  ---^I-------I -
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Table 1: Frequency of User Research Articles Involving Commercially
Supplied vs. User-Developed Chemical Methods as a Function
of Manufacturer of Analyzer Used
Number of Articles Found Reporting
Research by User Personnel
Only (a) which Involved:
Manufacturer-
"Commercialized"(b)
Chemistries
Researcher-
Developed
Chemistries
,Was performed
on Automated
Clinical Chemistry.
Analyzers
Manufactured by.:
2 Technicon
0 DuPont
6 Abbott Labs
(DuPont vs. Technicon p .02
DuPont vs. Abbott Labs P = .04
Fisher exact)
Notes: (a)Since our goal is to determine user ability to and
interest in modifying manufacturer-supplied chemistries
for the analyzer brands listed above, papers written
by manufacturer personnel only or written jointly by
manufacturer and user personnel are excluded. (One
paper thus excluded was written jointly by a DuPont
and user research team and reported a researcher-
developed chemistry for the aca (11). Via telephone
inquiry we determined that the test packs used in the
research were filled to the researchers specifications
at the DuPont plant. This would be in line with the
interviewees hypothesis that users would find it hard
to do this task themselves).
(b) DuPont commercial chemistries are always sold to the
user prepackaged (see text). Technicon "commercialized"
chemistries may be either pre-mixed reagents sold to
the user or Technicon-specified formulas which the user
mixes up in his laboratory as needed.
20
6
5
2
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speculation of interviewees regarding the pattern of research usage of Technicon,
DuPont and Abbott Lab's automated clinical chemistry analyzers. For our sample
of articles, we find p ,.02 that users are as likely to conduct research involv-
ing non-commercial vs. commercial chemistries on DuPont vs. Technicon analyzers
and p = .04 that users are as likely to conduct research involving non-commercial
vs. commercial chemistries on DuPont vs. Abbott Labs equipment (Fisher exact).
5.0 An Alternate Explanation
While the test just described was targeted very specifically towards
the speculation of interviewees that the DuPont automated clinical chemistry
analyzer was less appropriate than Technicon and Abbott Labs analyzers for user
development and implementation of test methods due to the design of its reagent
system, alternate explanations for our table 1 data may be suggested. We will
therefore briefly address one such which has occured to us - others may occur to
the reader - as follows: As we mentioned in the introduction, it has been shown
that, in some instances, user innovation activity appears to diminish over time(5)
Is it possible that this effect could explain our.data? Obviously, we have
controlled for any time-effect impacting the whole automated clinical chemistry
analyzer category by measuring user innovation activity during the same, 1975-78
time period for all analyzers examined. But what if researcher interest in a
particular analyzer brand characteristically changes with the passage of years
since that brand's commercial introduction (perhaps typically diminishing over
the years as the equipment becomes obsolete - or perhaps typically rising over
the years as researchers become more cognizant of the equipment's research poten-
tial). Since the first Technicon analyzer was commercially introduced in 1955,
the DuPont.analyzer in 1970 and Both Abbott Labs analyzer models (the ABA-100
and the ABA-50) in 1972, the pattern of user method development levels which we
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have observed (Technicon and Abbott Labs high, DuPont low) does not appear
consistent with this type of explanation.
6.0 Potential Value of User Method
Development Activity to Analyzer
Manufacturers
In the previous section we have found support for the notion that
aspects of the design of functionally very similar products (automated clinical
chemistry analyzers) can have a major impact on the level of user innovation
activity related to those products (development of test methods for use on
analyzer equipment). To some extent, the interest of this finding for innovation
researchers and practitioners depends on whether some of the user innovation
activity observed is directed toward development of methods of potential 'value
to many users. The methods of interest to the most users - and thus of greatest
commercial interest to analyzer manufacturers - are, of course, those methods
most frequently used by clinical chemistry laboratories. It therefore seemed
to us that one might make an initial assessment of the issue noted above by
determining whether user innovation activity can be seen in the development of
the "analyzer compatible" versions of a sample of commonly used test methods
currently sold commercially by analyzer manufacturers.
Because of the complexity of the data collection task to be described
below, we decided to restrict our investigation to the most commonly-used test
methods offered by Technicon and DuPont only for use with their analyzer equip-
ment. Our sample of such methods was selected in a straightforward manner:
a list of the 20 most frequently performed clinical chemistry tests was obtained.9)
Automated methods for performing 20 of these tests are offered by Technicon and
18 by DuPont, which gives us a sample of 38 "adaptations to automation" for
study. (Recall that different types of analyzers have different performance
I 11
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characteristics, and that therefore developing an analyzer-compatible version
of test method A for a DuPont analyzer is independent.of the task of developing
an analyzer compatible version of the same method for a Technicon analyzer).
In the numerous instances in which a manufacturer has offered different methods
for the performance of a given test on his equipment with the passage of time,
the method currently offered on the most recently.introduced equipment model
was the one we selected for-inclusion in the sample. (Thnicon's latest model
is trade-named the "SMAC High-Speed Computer-Controlled Biochemical Analyzer".
The only model DuPont has ever introduced -- and thus its latest model -- is
trade-named "ACA -- Automated Clinical Analyzer".) The tests comprising our
sample will be found explicitly identified in note a, table 2.
Data collection work for this sample involved literature searches and
structured interviews with manufacturer and user personnel. Work on a case
would usually begin with a search of the literature for papers related to the
test method being examined. Authors whose papers were found germane were contacted
and were told that we were interested in exploring the early history of the
application of the innovation discussed in their papers to autoanalyzers. We
then asked them for the names of fellow-experts with user and/or manufacturer
and/or other relationships to the innovation who might have a good knowledge of
these matters. Finally, we asked these initial.contacts for any knowledge which
they themselves might have. on the topic of interest. Individuals identified for
us by initial contactees were contacted in turn, and the process repeated until
we felt we had the information we needed well documented.
During our literature searches, we fund two data sources especially
useful:
- The MEDLINE computerized index of the medical literature described
previously
- "Product labeling" -- U.S. Food and Drug Administration terminology
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for methods-relating information which the suppliers of clinical
test chemistry methods make available to their customers. We
acquired product labeling from both Technicon and. DuPont for all
methods in our sample. These contained references to publications
on chemical test methods used and, in the case of Technicon labeling,
also contained references to publication reporting adaption of methods
to automation and the results.-
6.1 Findings
Our goal in this portion of the study was to determine whether user
innovation activity could be ovserved in the development of commonly-used
analyzer-compatible test methods offered commercially by Technicon and DuPont.
The measure used in table 2 - did a user develop and report on the use of a
sampled method on a manufacturers equipment before that manufacturer made it
commercially available - was designed to indicate both the appropriateness and
the timeliness of this subset of user method development activity. Observe, however,
that the measure does not indicate whether analyzer manufacturers exploited the
user work or developed essentially the same results independently: It only
indicates that the user results were available.
Insert Table 2 Here
In table 2 we see the interproduct difference in user innovation
activity which we would expect from our table 1 findings, No analyzer
compatible test methods in our sample which DuPont offers commercially for
use on its aca were developed first by users insofar as we could determine,
while 74% of the sampled analyzer-compatible methods which Technicon offers
commercially for use on its SMAC model were performed first
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Table 2: Adaptations to Automation of Test(a) Methods
Offered Commercially by Equipment Manufacturers
Were First Performed (b ) By:
To Users Of:
Equip. Reagent
%user user(C) Mfr. Mfr. NA Total
I i
DuPont ACA 0 0 18 0 0 18
I i
i i
I
I I
Technicon
SMAC (d) 74 | 14 4 1 1 20
I I
I I
I I
I I I
. I
, p < .0001 (Fisher exact)
(a)
Notes: As explained in the text, the sources of adaptation to automation
of the twenty clinical chemistry tests performed with greatest
frequency in 1977 were examined. The identity of these twenty
tests: Albumin; Alk Phos; Calcium; Chloride; Cholesterol; CPK;
Creatinine; Direct (conjugated) Bilirubin; Glucose; SGOT; SGPT;
Inorganic Phos; LDH; Potassium; Sodium; Total Protein; Triglycer-
ides; Urea Nitrogen; Uric Acid. (All 20 are offered by Technicon;
DuPont offers all by potassium and sodium).
(b)The measure used: Did we determine that one or more "users" (see note
(c) for definition) published a report of adaptation and clinical use
of a given test method on DuPont or Technicon equipment with publi-
cation date prior to date of commercial introduction of that method
(as reported by equipment manufacturer personnel).
(C)Those who performed the adaptation to automation of a test method
were coded as "users" on the basis of professional affiliation
rather than motive for performing the work. (We felt that data
on the former would be the more reliable measure when collected
retrospectively.) In the event, all except three "users" were
found to be professionals working in clinical laboratories of
non-profit hospitals. The three exceptions worked in an Automated
Methods Lab in a VA Hospital -- affiliated with that hospital's
clinical lab but not themselves performing day-to-day lab work.
(d)The SMAC is tha latest of several models of Technicon Analyzers
utilizing the principle of "continuous flow analysis" (see text). Some
of the methods offered by Technicon to SMAC users were adapted to
continuous flow on the SMAC, others were adapted on other models of
continuous flow analyzers and found appropriate for use an SMAC as well.
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by users (p < .0001, Fisher exact). We thus speculate that, user method develop-
ment activity involving automated clinical chemistry analyzers is not exclusively
directed to exotica: Users sometimes develop methods of general interest.
7.0 Findings Regarding the Generalizability
of Firm Innovation Patterns Seen
In this paper we have carefully examined only one of the categories
of innovation which would be of concern to firms wishing to manufacture automated
clinical chemistry analyzers - development of test methods adapted for use on
automated equipment. In this category we found users more strongly involved
in innovation work related to Technicon and Abbott Labs equipment than to DuPont
equipment. This does not mean, however, that Technicon and Abbott Labs can assume
that users are involved in all categories of its analyzer innovation work or that
DuPont can assume the opposite. Indeed, some limited data we have for DuPont
and Technicon regarding three other categories o work which would be of interest
to automated clinical chemistry analyzer manufacturers suggests strongly that
such an assumption would not be warranted;
In our sample of commonly-used clinical test methods appropriate for
use on automated equipment, we found that, invariable, the method studied was
adapted from pre-existing manual methods. (The work involved in these adapta-
tions ranged from easy to difficult. Where the task was easy, all that might
have been involved, for example, was adjustment of the concentrations of the
serum sample and/or reagents specified for the manual version of the test so
that the test results fall within the linear range of the automated equipment's
detection instrumentation. Where the task was difficult, nothing would fit:
side reactions which didn't affect the manual performance of the test would
badly interfere with the operation of the automatic equipment. Steps taken
to solve this problem would also have the unintended effect of reducing test
sensitivity to an unacceptable level -- and so on.)
- 15 -
As a rapid check on'thesource of the manual methods behind the
adaptations we examined, we turned to the "package labeling" which, as we noted
earlier, we had acquired for each of the method adaptations -in our sample.' Since,
in each instance, this material referenced publications regarding the manual
method upon which the adaptation described was based, we were able to quickly
retrieve papers by the method developers. When these papers supplied the organiz-
ational affiliation of the developers, we recorded it, with the results shown in
table 3.
Insert Table 3 Here
Note that, for this category of innovation work, both manufacturers
equally relied on innovation by members of non-profit institutions. (As we did
not contact the authors of these papers, we are unable to report more precisely
on the developers' relationship to the method they developed: On the face of it,
they could have been either users or research scientists with no interest in
the methods' practical applications).
- We briefly examined an additional category of innovation task which must
be accomplished if a manufacturer of autoanalyzer equipment wishes to premix and sell
the reagents which are required for test methods adapted for his equipment. In
essence, this task involves stabilizing the reagents so that they will have
shelf life sufficient to survive the time lags expected in the distribution and
use cycles. This task can be quite difficult in the instance of certain reagents.
We did not study this category on a case-by-case basis, we can report anec-
dotally that users and manufacturers alike informed us that this task is "almost
"Lon--raaa--·- -^--·--·----r^ ______
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Table 3: Source of Manual Chemical Test Methods Adapted
For Automation of DuPont ACA and Technicon SMAC-
Adaptation of Method
Offered by
DuPont
Affiliation of Method Developer
Manufacturer (a) Non-Profit (b)
2
.Technicon
16
2 18
Notes: (a)Includes any commercial manufacturer of autoanalyzer
equipment and/or reagents
(b)Includes hospital, university and institute affiliations
Data source: "Package labeling" for twenty most frequently
requested tests (cf. table 2 for explicit identification of
tests. Technicon labeling obtained from Technicon Corp.,
Tarrytown, New York, DuPont labeling obtained from DuPont
Company, Instrument Products Automatic Clinical Analysis
Division, Wilmington, Deleware.
--
III
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always" undertaken by the reagent manufacturer.
- Finally a category of innovation related to automated clinical chemistry
analyzers - equipment improvement innovations - does show the same interbrand differ-
ences in user innovation activity which we observed in the instance of user develop-
ment of chemical test methods. Our sample of equipment improvement innovations was
generated by first identifying and listing the major equipment changes offered
by each manufacturer after bringing their first clinical chemistry analyzers to
market. These listings were made with the aid of knowledgeable manufacturer
personnel primarily. Next, we discussed these lists with users and manufacturer
personnel and arrived at an informal consensus as to which of the commercially
introduced improvements had offered a "significant increment in functional
utility to the user relative to that provided by the equipment previously commer-
cially available from that manufacturer" (No formal measure of consensus was
used). The samples which resulted from this procedure are explicitly identified
along with our findings related to them in Table 4. Data collection for this
sample involved telephone interviewing of expert user and manufacturer personnel
only. While multiple sources were queried regarding each innovation, we did not
follow our usual practice in this sample of also validating our data via an inde-
pendent literature search.
Insert Table 4 Here
As table 4 shows, we were able to identify 12 Technicon equipment
improvement innovations which met our selection criterion, but only one such
innovation in the instance of DuPont: DuPont equipment, we found, has remained
almost unchanged since its commercial introduction. (12) (We do not mean to
suggest via this observation that DuPont is somehow "less innovative" than
Technicon. As we will discuss in a later section, each company's pattern of
equipment improvement might well be appropriate to its overall commercial strategy.
o ______
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Table 4: Source of Commercialized Hardware -- Embodied Innovations
in DuPont and Technicon Autoanalysis Equipment
First Device Routinely-
Used in Clinical Lab
Developed and Built by: a)
Dupont Autoanalysis Equipment Innovations: a
First commercialized model mfr.
Improved computer control mfr.
Technicon Continuous'Flow Autoanalysis Equipment '
Innovations: ;
First commercialized model user
Major detector improvements
flourometer ' user
flame ionization photometer , mfr.
ion selective 'electrodes mfr.
Major flow cell improvements
smaller volume/adjacent debubbler user
bubble-gated mfr. (b)
Major dialysis improvements
shorter flow path/type C membrane ' mfr.
type H membrane , mfr.
Other major improvements
multiple channel equipment a user
physician-readable chart output user
Reduction in sample carryover
reduced tubing diameter , user
air/sample/reagent pump syncroni- J
zation - mfr.
Multiple bubble introduction by
sample probe , mfr.
computer compensation for carry-
over a user
notes:
O(aur source coding is based on whether manufacturer'or user'was first
to develop and build a device displaying the'operating principles and
function of the later-commercialized device. The precise embodiment
of the user and manufacturer versions may differ,
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however. (Thus, user versions of the "smaller-volume flow
cell with adjacent debubbler" were assemblies while the
commercial version was near-monolithic).
(b)A very innovative user, Ralph Thiers, is well known for having
contributed to this innovation, but in his view, Technicon
produced the first commercializable design in-house, and we
concur;
(C)Developed by Dr. Leonard Skeggs, the same innovative user who
developed the first continuous flow autoanalyzer. Although
well connected with Technicon at the time of this development,
Skeggs was not employed by Technicon. He built the first
device "in his basement" and clinically evaluated it in his
VA lab before turning it over to Technicon for commercial
manufacture.
- -~
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Technicon might well wish to emphasize equipment sales, and thus have an incen-
tive to introduce equipment improvements which would induce users to "trade up".
DuPont, on the other hand, might wish to emphasize sales of its disposable test
packs. If so, it would have an incentive not to make equipment changes which
would obsolete equipment already in the field, but rather to try and keep up
with evolving technology via equipment-compatible changes in the test pack portion
of the system).
Note that the single DuPont equipment improvement innovation identified
which offered a major increment of functional utility to the user -- an internal
computer of greater capability -- had a DuPont source. No user development was
involved insofar as we could determine. Although the DuPont equipment innovation
sample is unfortunately not large enough to test the hypothesis, we would suggest
that it is only logical that all or most such DuPont equipment improvement
innovations would come from an in-house source. Automated clinical chemistry
analyzers, after all, are designed to perform chemical procedures. If manufact-
urer-offered equipment is appropriate for the performance of manufacturer-
offered chemical procedures; user incentive to change the equipment would be
derived from user interest in performing non-standard chemistries on the equip-
ment. And, as we saw in an earlier section, certain design features of the DuPont
equipment militate against users turning to it for implementation of non-standard
work. Similar logic can be used, we suggest, to explain the observed presence
of user-development activity related to our sample of commercialized Technicon
equipment improvement innovations. Users, as we have previously seen, do find
Technicon equipment suitable for development of non-standard chemical methods.
It is therefore logical that they would sometimes have a derived need for
related equipment innovations -- and have an incentive to develop these as
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well.
7.0 Relationship of Findings
to "Reinvention"
The findings reported in this paper are related to and support the
concept of "reinvention" which Rogers et al. (1 4 ) have developed and empirically
examined. Rogers points out that students of diffusions research have tended
to regard an innovation as invariant: potential users of the innovation are seen
as having only the two choices of (a) adopting the innovation precisely as
offered or (b) rejecting the innovation. In the paper cited above, data is
provided to show that, in the instance of an information processing tool named
GBF/DIME, users often took a third option: their adoption behavior included
modification ("reinvention") of the innovation as received so that it would
better conform to their needs.
In the work reported on here, we saw Rogers' reinvention ("user innov-
ation" in our terminology) being carried out by some users of one firm's product --
It should be noted that the sample of commercialized equipment improvement
innovations identified in table 4 are not the only ones which have been
developed over the years. Recall that our sample selection methodology
involved asking interviewees to list commercialized hardware improvement
innovations. Thus, major improvement innovations developed by users and
replicated in limited numbers by members of the user community but never
offered commercially by the equipment manufacturer are excluded. The litera-
ture shows many such innovations by equipment users such as the adaptation of
an Atomic Absorbtion instrument as a detector on Technicon systems. (13) Such
innovations offer Technicon a pool of prototyped and field proven new products
which they could offer commercially if they should someday decide there is a
market sufficient to make action worthwhile.
 '^"111"1---^-1-^I----- 
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but not by users of a similar product supplied by another firm. Thus, we may
perhaps contribute to the reinvention concept by suggesting that the relative
frequency of reinvention vs.. straightforward adoption observed can differ for
"equivalent" products, and may be controllable by the manufacturers of some
products via product designs which make user reinvention an easy or a difficult
task.
8.0 Costs and Benefits of
User Innovation Ability
Our finding that a firm sometimes can influence the level of user
product innovation it experiences does not indicate whether a given firm will
be interested in doing so. Nor does it suggest whether a manufacturer's inter-
est might lie in the direction of encouraging or discouraging product-related
innovation by users and other non-manufacturer personnel. A review of the
impact of the level of user method development activities on the strategies
and fortunes of Technicon and DuPont in the autoanalyzer field suggests that
the considerations which determine a particular firm's stance on these matters
can be quite complex, and we now turn to an exploration of this matter.
First, what has Technicon gained from user method development activity?
Anecdotal discussions with knowledgeable users and manufacturer personnel
suggest the following major categories of benefit:
- increased instrument sales
- free RD on methods within clinical chemistry
- user involvement in development and proof of value of applications
outside of clinical chemistry, (Approximately 10% or $20 million of Technicon's
1977 analyzer sales were made to industrial application customers. DuPont aca
personnel knew of no instances in which aca was applied to a use other than
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clinical chemistry analysis.)
The related costs to Technicon suggested to us:
- costs of screening user innovations and selecting those which they
should perform "product engineering" work on and offer for commercial sale..
- inability to capture all sales of reagent used on their machines.
This last is tha major cost which may be attributable to the accessibility
of Technicon equipment to innovative users, and we will explore it further.
Both Technicon and DuPont manufacture automated clinical chemistry
analyzers and reagents appropriate for use in their equipment. Over the
years, the commercial importance of reagent sales to both firms has risen
relative to that of analyzer equipment sales because: the market for such
equipment has begun to approach saturation; more equipment in the field means
greater reagent usage. While DuPont has been able to capture 100% of reagent
sales to users of its analyzers, Technicon has lost perhaps 30%(15)of this
market to competing reagent manufacturers. Since Technicon's total reagent
sales in 1977 were approximately $50 million, one can see that this loss -- both
direct and in terms of competition-induced reduction -- is monetarily significant.
Interestingly, it is likely that the same difference in the design of the two
firms' analyzer equipment, discussed earlier as causes of the observed interproduct
differences in levels of user method innovation, may also play a role in the
observed difference in Technicon and DuPont's success in the capturing of reagent
sales. As noted earlier, DuPont's reagents, are sold and used in an elaborate
patented package. A would-be competitor must legally contest these patents or
"design around" their claims and must invest in expensive tooling for package
production if he wishes to produce a substitute compatible with the DuPont
analyzer equipment. Technicon's reagents, on the other hand, are supplied to
the user in simple bulk containers easily obtainable by anyone.
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9.0 Summary
The data presented in the preceding pages supports the notion that
the level of user product innovation experienced can differ greatly between
functionally similar products. In the particular sample we have studied, it
appears that the principal cause of the variation in user innovation activity
observed appears to lie in the ease with which a would-be-user-innovator can
modify a manufacturer's product to suit his particular needs. Doubtless this
product design variable has an influence on the level of user innovation exper-
ienced by the manufacturers of many types of product in addition to clinical
chemistry autoanalyzers: for example, the degree to which a product design
allows users convenient access to the software of computerized instruments,
word processors, cash registers, etc. might will have an impact on the level
of user innovation activity involving that equipment. Note, however, that we
do not mean to imply that any easy-to-modify product will induce related user
innovation activity. Probably, user interest in modifying a given product is
independent of product design: An easy-to-modify product design will simply
facilitate the work of interested user-innovators and perhaps determine which
of several competing products they will choose to work with. Further note that
we do not mean to suggest that product design is the only or usual cause of
interproduct variations in the level of user innovation activity. Indeed, we
suspect that further research will show that numerous variables controllable
at the level of the individual firm can influence that level. Such a prospect
complicates the life of the researcher but should please the innovation practi-
tioner - who would gain additional degrees of freedom in management of the
innovation process.
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